This article is more than 5 years old. Information may no longer be current.

Eight important updates in gastrointestinal cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HemOnc Today presents eight research advances regarding genetic mutations, potential biomarkers and treatment that may be relevant to your practice and help in the management of patients with gastrointestinal cancer.

• Patients with ALK-, ROS1- or NTRK-rearranged tumors defined a rare subtype in metastatic colorectal cancer associated with poor outcomes, for which early recognition could allow for tailored treatment plans. Read more.
• Colorectal cancer mortality rates have increased steadily among white individuals who are younger than standard screening age. Read more.
• Trifluridine and tipiracil (Lonsurf, Taiho Oncology) — also called TAS-102 — plus bevacizumab (Avastin, Genentech) appeared safe and effective for the treatment of patients with metastatic colorectal cancer in the refractory setting, according to results from the C-TASK FORCE study. Read more.
• Researchers observed germline mutations in pancreatic cancer susceptibility genes among patients with pancreatic cancer who did not have significant family history of the disease. Read more.
• SillaJen and NCI entered a cooperative research and development agreement to evaluate Pexa-Vec (JX-594, SillaJen) — an oncolytic immunotherapy — for the treatment of patients with advanced colorectal cancer. Read more.
• The addition of stereotactic body radiotherapy to chemotherapy extended OS among patients with unresectable pancreatic cancer. Read more.
• Mutated gene and mutation type can dictate at which age patients with Lynch syndrome, which predisposes individuals to colorectal and other cancers, should begin cancer surveillance. Read more.
• The FDA approved nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan. Read more.